Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer.
- 1Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- 2Department of Anesthesiology and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- 3Department of Gastrointestinal Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China. Electronic address: [email protected].
Abstract
Background
Antibody-drug conjugate (ADC) activity and target-dependent on-target/off-tumor toxicity depends in part on which cells express the target antigen, a feature that bulk assays cannot resolve.Methods
We analyzed a publicly available whole-transcriptome CosMx breast tumor dataset including 154,816 cells and 18,934 genes. Eleven clinically relevant ADC targets were profiled across seven annotated lineages. Findings were contextualized using TCGA-BRCA bulk transcriptomes (1,097 tumors and 114 normal tissues) and assessed in two public Xenium breast cancer specimens.Results
HER2 (ERBB2), TROP2 (TACSTD2), HER3 (ERBB3), NECTIN4 and MUC1 were enriched in tumor epithelium. B7-H3 (CD276) was highest in endothelial and myoepithelial cells, with similar mean expression in stromal and tumor cells. PSMA (FOLH1) was enriched in endothelium. TCGA-BRCA tumor-normal differences did not identify these cellular sources. No overall-survival association remained after multiple-testing correction or covariate adjustment. HER2 and TROP2 tumor enrichment recurred in both Xenium specimens, whereas EGFR was not tumor restricted.Conclusions
Cell-resolved spatial profiling separated ADC targets enriched in tumor epithelium from those expressed in vascular and stromal compartments. B7-H3 and PSMA localization was consistent with prior immunohistochemical reports and is confirmatory. These RNA-level results do not establish surface-protein abundance, ADC response, or clinical toxicity. Low-abundance microenvironmental findings remain based on a single discovery specimen and require protein-level validation. Protein-level confirmation, and correlation with ADC efficacy and toxicity, are required before these maps can inform clinical decisions.
Related
- Domain-resolved epitope mapping of B7-H3-targeting VHH-Fcs defines isoform-selective binders for antibody-drug conjugate development
- Epitope-resolved Epstein-Barr virus antibody mapping identifies disease-stratifying signatures in nasopharyngeal carcinoma
- Human-Guided Agentic AI for End-to-End EHR Research: Sequential Antibody-Drug Conjugate Pathways in Breast Cancer
- 535 BC3195, a novel cadherin-3 targeting antibody drug conjugate, combined with pembrolizumab in patients with advanced solid malignancies: preliminary results from a phase I/II study (BC3195-103/G36)
- Radiotherapy-Conditioned Antibody–Drug Conjugate Activity: Molecular Mechanisms, Therapeutic Windows and Organ-Specific Toxicity
BibTeX
@article{zhao2026cellresolved,
title = {{Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer.}},
author = {Yang Zhao and Zhixia Bai and Tao Li},
journal = {Translational oncology},
year = {2026},
month = oct,
doi = {10.1016/j.tranon.2026.103068},
url = {https://europepmc.org/article/MED/42863323},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer.
AU - Yang Zhao
AU - Zhixia Bai
AU - Tao Li
PY - 2026
DA - 2026/10/12
JO - Translational oncology
DO - 10.1016/j.tranon.2026.103068
UR - https://europepmc.org/article/MED/42863323
AB - Background Antibody-drug conjugate (ADC) activity and target-dependent on-target/off-tumor toxicity depends in part on which cells express the target antigen, a feature that bulk assays cannot resolve.Methods We analyzed a publicly available whole-transcriptome CosMx breast tumor dataset including 154,816 cells and 18,934 genes. Eleven clinically relevant ADC targets were profiled across seven annotated lineages. Findings were contextualized using TCGA-BRCA bulk transcriptomes (1,097 tumors and 114 normal tissues) and assessed in two public Xenium breast cancer specimens.Results HER2 (ERBB2), TROP2 (TACSTD2), HER3 (ERBB3), NECTIN4 and MUC1 were enriched in tumor epithelium. B7-H3 (CD276) was highest in endothelial and myoepithelial cells, with similar mean expression in stromal and tumor cells. PSMA (FOLH1) was enriched in endothelium. TCGA-BRCA tumor-normal differences did not identify these cellular sources. No overall-survival association remained after multiple-testing correction or covariate adjustment. HER2 and TROP2 tumor enrichment recurred in both Xenium specimens, whereas EGFR was not tumor restricted.Conclusions Cell-resolved spatial profiling separated ADC targets enriched in tumor epithelium from those expressed in vascular and stromal compartments. B7-H3 and PSMA localization was consistent with prior immunohistochemical reports and is confirmatory. These RNA-level results do not establish surface-protein abundance, ADC response, or clinical toxicity. Low-abundance microenvironmental findings remain based on a single discovery specimen and require protein-level validation. Protein-level confirmation, and correlation with ADC efficacy and toxicity, are required before these maps can inform clinical decisions.
SN - 1936-5233
ER -